Ketoacidosis associated with protease inhibitor therapy
Besson, C.; Jubault, V.; Viard, J.P.; Pialoux, G.
Aids 12(11): 1399-1400
1998
ISSN/ISBN: 0269-9370 PMID: 9708427 Document Number: 533788
Document emailed within 1 workday
Related Documents
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679Cabot de Vega, E.; Fontecha Gómez, B.J.; Solé Arnau, R.; Pedrol Clotet, E. 1999: Peripheral lipodystrophy associated with protease inhibitor therapy Revista Clinica Espanola 199(8): 546-547
2000: Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy MMW Fortschritte der Medizin 142(3 Suppl): 41
Sangraula, H.; Sharma, K.K.; Dwivedi, S. 2001: Antiretroviral protease inhibitor therapy leads to hyperglycaemia, hyperlipidaemia and lipodystrophy National Medical Journal of India 14(6): 347-348
Ritt, M.J.; Hillebrand-Haverkort, M.E.; ten Veen, J.H. 2001: Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy Acta Chirurgiae Plasticae 43(2): 54-56
2000: Holding option open for subsequent treatment. Beginning therapy with a protease inhibitor MMW Fortschritte der Medizin 142(3 Suppl): 8-9
Bard, J-Marie.; Lassalle, Régis.; Capeau, J.; Bach-Ngohou, K.; Nazih-Sanderson, Fçoise.; Rémy, Gérard.; Reynes, J.; Ecobichon, J-Luc.; Savès, M.; Raffi, Fçois. 2006: Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy Antiviral Therapy 11(3): 361-370
Hammer, S.M.; Vaida, F.; Bennett, K.K.; Holohan, M.K.; Sheiner, L.; Eron, J.J.; Wheat, L.Joseph.; Mitsuyasu, R.T.; Gulick, R.M.; Valentine, F.T.; Aberg, J.A.; Rogers, M.D.; Karol, C.N.; Saah, A.J.; Lewis, R.H.; Bessen, L.J.; Brosgart, C.; DeGruttola, V.; Mellors, J.W. 2002: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial JAMA 288(2): 169-180
Uchishiba, M.A.; Colley, C.; Strausbaugh, L.; Ward, T. 1997: Can ongoing education by a clinical pharmacist decrease the mean viral burden for patients on protease inhibitor therapy? Pharmacotherapy 17(5): 1122
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Traber, D.L.; Adams, T.; Sziebert, L.; Williams, P.; Traber, L.D. 1984: Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor Circulatory Shock 13(4): 319-323
Taylor, B.S.; Hunt, G.; Abrams, E.J.; Coovadia, A.; Meyers, T.; Sherman, G.; Strehlau, R.; Morris, L.; Kuhn, L. 2011: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa AIDS research and human retroviruses 27(9): 945-956
Della Porta, P.; Soeltl, R.; Krell, H.W.; Collins, K.; O'Donoghue, M.; Schmitt, M.; Krüger, A. 1999: Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo Anticancer Research 19(5b): 3809-3816
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Fisker, F.; Møller, N.; Lauritzen, E.S. 2019: Sodium-glucose-cotransporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis Ugeskrift for Laeger 181(21)
Piliero, P.J. 2004: Atazanavir: A novel once-daily protease inhibitor Drugs of Today 40(11): 901-912
Viciana, P.; Miralles-Martín, P.; Knobel, H.; Gatell, J.M. 1998: Prevention of opportunistic infections in the protease inhibitor era Enfermedades Infecciosas y Microbiologia Clinica 16 Suppl. 1: 1-10
Gastaldi, G.; Mattiello, A. 1971: Effect of a protease inhibitor on bacterial multiplication Pathologica 63(923): 223-231
Juhász, S. 1983: Studies on the protease inhibitor of Klebsiella aerogenes Acta Veterinaria Hungarica 31(4): 121-123
Bierl, H. 2003: Atazanavir--first protease inhibitor for one dose administration Deutsche Medizinische Wochenschrift 128(39): 2039-2040